Talis Biomedical Corporation
TLIS · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -51.7% | 98.7% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -267.1% | -311.9% | 92.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -18,979.5% | -9,462.9% | -21,548.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -17,856.2% | -8,913.9% | -20,634.2% |
| EPS Diluted | -4.86 | -7.15 | -7.4 | -8.62 |
| % Growth | 32% | 3.4% | 14.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |